Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-04-05
2011-12-06
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021700, C514S021800, C514S021900, C514S021910, C530S328000, C530S329000, C530S330000, C530S331000, C424S185100, C424S193100
Reexamination Certificate
active
08071552
ABSTRACT:
The present invention describes compounds comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compounds of the present invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X1—X2—X3—X4—X5—X6—X7—X8, wherein: X1is Phe, or is absent; X2is His or Ala; X3is Glu, Ser, Ala, Asn, Lys, or Cys; X4is Asn, Phe, Gln, Pro, Ser, or Ala; X5is Trp; X6is Pro, Arg, Glu, Gly, Cys, or Lys; X7is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X8is Phe, Gly, or is absent.
REFERENCES:
patent: 5028592 (1991-07-01), Lipton
patent: 2006/0233805 (2006-10-01), Figdor et al.
patent: 197 49 277 (1999-05-01), None
patent: 2002 187899 (2002-07-01), None
patent: WO 96/12741 (1996-05-01), None
patent: WO 98/37099 (1998-08-01), None
patent: WO 03/064457 (2003-08-01), None
patent: WO 2004/026326 (2004-04-01), None
patent: WO 2005/019258 (2005-03-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495, 1994.
Van Noort et al, International Review of Cytology 178: 127-205, 1998.
Heck et al, Proc Natl Acad Scie 93:4036-4039, Apr. 1996.
Harlow et al, in Antibodies a Laboratory Manual, 1988, Cold Spring harbor laboratory publication, Cold Spring Harbor, NY, p. 321-323.
Jouault, T., et al; “Peptides That Mimic Candida Albicans-Derived Beta-1,2-Linked Mannosides”;Glycobiology, IRL Press, GB; vol. 11, No. 8, pp. 693-701; Aug. 2001; XP009026488.
Santamaria, H., et al; “Identification of peptide sequences specific for serum antibodies from human papillomavirusinfected patients using phage display libraries”;Clinical Immunology(Orlando); vol. 101, No. 3, pp. 296-302; Dec. 2001; XP009045311.
Anni, H., et al; “Selection of phage-display library peptides recognizing ethanol targets on proteins”;Alcohol(Fayetteville, NY); vol. 25, No. 3; pp. 201-209; Nov. 2001; SP009045307.
Miura, Y., et al; “Peptides binding to a Gb3 mimic selected from a phage library”;BBA—General subjects, Elsevier Science Publishers, NL; vol. 1673, No. 3; pp. 131-138; Aug. 4, 2004; XP004523265.
Gloeckner, et al; Database EMBL (Online); Oct. 1, 2003; Database Accession No. Q7USF5; XP002321307.
Galagan, et al; Database EMBL (Online); Mar. 1, 2004; Database Accession No. Q7RYN4; XP002321308.
Chaudhary, et al; Database EPO Proteins (Online); Jun. 14, 2002; Database Accession No. AX411500; XP002321309.
Chaconas, et al; Database GENESEQ (Online); Feb. 12, 2004; Database Accession No. ADF72653; XP002321310.
Beasley, et al; Database EPO Proteins (Online); Oct. 26, 2001; Database Accession No. AX256979; XP002321311.
Mossalayi Mohammad Djavad
Moynet Daniel
Rambert Jerome
Self Christopher R.
Vincendeau Philippe
Huynh Phuong
Nixon & Vanderhye
Universite Bordeaux 2
LandOfFree
Peptides and peptidomimetics binding to CD23 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides and peptidomimetics binding to CD23, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and peptidomimetics binding to CD23 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313414